CME: Reducing the Impact of Influenza Viral Load on Patient and Community Health

Reducing the Impact of Influenza Viral Load on Patient and Community Health

Reducing the Impact of Influenza Viral Load on Patient and Community Health

The flu season is upon us, but the good news is that we have more options to not only treat it, but also reduce the spread of this illness.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The newer option that’s available to treat the flu is not a neuraminidase inhibitor, but an endonuclease inhibitor, and both work differently in their approach to reducing the viral load and the viral shedding of the flu virus. This activity will discuss how we can integrate these options into personalized treatment plans and the impact of influenza on at-risk and high-risk individuals.

    Since the launch of the activity, the US FDA has approved a new indication for baloxavir marboxil to include the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours, who are otherwise healthy, or who are at high risk of developing flu-related complications

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Paul P. Doghramji, MD
    Medical Director of Health Services
    Ursinus College
    Collegeville, PA

    Dr. Doghramji has nothing to disclose.

    John J. Russell, MD
    Director Family Medicine Residency
    Abington Memorial Hospital
    Abington, PA

    Dr. Russell is a speaker for Sanofi Pasteur.

    Reviewers/Content Planners/Authors:

    • Stephen Chavez has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the biologic pathways and related MOAs for antiviral agents effective against influenza A & B
    • Evaluate the impact of influenza on at-risk and high-risk individuals and communities
    • Integrate newer and emerging influenza agents into more personalized treatment plans
  • Target Audience

    This activity is designed to meet the educational needs of pediatricians, primary care physician, infection disease specialists and hospitalists who see patients 12 and older with the flu as well as providers who manage high risk patients with pre-existing conditions such as allergists, pulmonologists, endocrinologists, cardiologists and geriatricians.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Genentech, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free